ArticleAsian Pacific journal of cancer prevention : APJCP2025
Association of GSTM1, NAT2 Gene Polymorphisms and Susceptibility to Renal cell carcinoma in Mongolia: A Case-Control Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the impact of glutathione S-transferase M1 (GSTM1) and N-acetyltransferase 2 (NAT2) polymorphisms on renal cell carcinoma (RCC) risk in Mongolian individuals, both independently and in combination with smoking and urinary tract diseases (UTDs).
methodsThis hospital-based case-control study included 88 histologically confirmed RCC patients and 88 cancer-free controls, matched by age and sex. Genotyping of GSTM1 and NAT2 polymorphisms was performed using PCR-RFLP.
resultsThere were 34 men and 54 women, with a mean age of 51.9 ± 13.2 years. The results revealed that NAT2 low acetylator genotype significantly increased risk of RCC (cOR=2.077, 95%CI=1.072-4.025, p=0.03). Notably, WT/M3 genotype was significantly associated with RCC risk (aOR=9.1, 95% CI=1.138-72.783; p=0.037). GSTM1-positive genotype significantly increased RCC risk when combined with NAT2 low acetylator genotypes (cOR=3.304, 95% CI=1.311-8.327, p=0.011). Among smokers, individuals with GSTM1-null genotype had an increased risk of RCC (cOR=4.654, 95% CI=1.458-14.86, p=0.009). Additionally, NAT2 low acetylator genotype significantly increased RCC risk in smokers (cOR=6.596, 95% CI=2.26-19.255, p=0.001). Furthermore, both GSTM1 and NAT2 genotypes were associated with significantly increased RCC risk following stratification by a history of urinary tract diseases.
conclusionThe findings suggest that the NAT2 WT/M3 polymorphism, along with smoking and UTDs, contributes to RCC susceptibility in Mongolian cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.